Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Glucagon-like peptide-1 therapy

Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002 18(6) 430-41. [Pg.387]

The approval of sitagliptin (1) by the U.S. FDA in 2006 established dipeptidyl peptidase IV (DPP-4) inhibitors as an important new therapy for the treatment of type 2 diabetes.4 7 DPP-4 inhibitors stimulate insulin secretion indirectly by enhancing the action of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (G1P). GLP-1 and G1P stimulate insulin secretion in a... [Pg.125]

Gallwitz, B. 2005. Glucagon-like peptide-l-based therapies for the treatment of type 2 diabetes mellitus. Treat. Endocrinol, 4, 361-370. [Pg.347]

Tzefos M, Olin JL. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus. Ann Pharmacother 2010 44 (7-8) 1294-300. [Pg.701]

See other pages where Glucagon-like peptide-1 therapy is mentioned: [Pg.657]    [Pg.401]    [Pg.57]    [Pg.386]    [Pg.388]    [Pg.2698]    [Pg.1353]    [Pg.108]    [Pg.147]    [Pg.38]    [Pg.179]    [Pg.46]    [Pg.405]    [Pg.472]    [Pg.227]   
See also in sourсe #XX -- [ Pg.1353 ]



SEARCH



Glucagon

Glucagon therapy

Glucagon-like peptide

Peptide glucagons

© 2024 chempedia.info